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Abstract
Actions to reduce greenhouse gas (GHG) emissions often reduce co-emitted air pollutants, 
bringing co-benefits for air quality and human health. Past studies1–6 typically evaluated near-term 
and local co-benefits, neglecting the long-range transport of air pollutants7–9, long-term 
demographic changes, and the influence of climate change on air quality10–12. Here we simulate 
the co-benefits of global GHG reductions on air quality and human health using a global 
atmospheric model and consistent future scenarios, via two mechanisms: a) reducing co-emitted 
air pollutants, and b) slowing climate change and its effect on air quality. We use new 
relationships between chronic mortality and exposure to fine particulate matter13 and ozone14, 
global modeling methods15, and new future scenarios16. Relative to a reference scenario, global 
GHG mitigation avoids 0.5±0.2, 1.3±0.5, and 2.2±0.8 million premature deaths in 2030, 2050, and 
2100. Global average marginal co-benefits of avoided mortality are $50–380 (ton CO2)−1, which 
exceed previous estimates, exceed marginal abatement costs in 2030 and 2050, and are within the 
low range of costs in 2100. East Asian co-benefits are 10–70 times the marginal cost in 2030. Air 
quality and health co-benefits, especially as they are mainly local and near-term, provide strong 
additional motivation for transitioning to a low-carbon future.
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Past studies have estimated that the human health co-benefits of GHG mitigation, by 
reducing co-emitted air pollutants, can be substantial1–2, and when monetized, range across 
many studies from a small fraction of GHG mitigation costs to exceeding them3–6. Here we 
estimate the co-benefits of global GHG reductions for air quality and human health for the 
first time using a global atmospheric model and future scenarios. We account for the 
influence of international air pollutant transport on health9, the effect of methane on global 
ozone8, increases in population and susceptibility to air pollution17, and economic growth 
that increases valuation. In addition to direct co-benefits of reduced co-emitted air pollutants 
(mainly local and immediate), we account for a second co-benefits mechanism, not 
previously quantified, in which slowing climate change decreases its effects on air quality 
(global and long-term). Climate change has been shown to increase ozone in the US and 
Europe (although the magnitude and patterns differ among studies), e.g., through increased 
photochemical reaction rates and biogenic emissions, and meteorological changes, but 
decrease ozone in remote areas. Fine particulate matter (PM2.5) may also increase in 
polluted regions, but these effects are less clear10–12.
Global GHG emission reductions are modeled in the Representative Concentration Pathway 
4.5 (RCP4.5) scenario18. The four RCP scenarios represent a range of global GHG 
emissions16, but as these scenarios were developed by different groups, their projections of 
future air pollutant emissions are inconsistent with one another19. Rather than comparing 
different RCP scenarios, we compare RCP4.5 with its associated reference scenario (REF). 
REF is a self-consistent representation of the future development of energy and land use, 
assuming an intermediate pathway for economic development and population growth, and 
assuming no climate policy. Regionally-specific air pollutant emissions in REF were 
developed such that air pollutant concentrations in each world region are consistent with the 
assumed future economic development to 210020.
Relative to REF, RCP4.5 applies a global carbon price across all economic sectors including 
terrestrial carbon through an efficient market, such that 2100 CO2 concentration decreases 
from 760 ppm to 525 ppm, and anthropogenic radiative forcing stabilizes at 4.5 W m−2. Air 
pollutant emission controls in REF are assumed to stay in place as the climate policy is 
implemented in RCP4.5. REF and RCP4.5 are therefore entirely consistent in their 
underlying assumptions, allowing differences in air pollutant emissions to be attributed 
uniquely to the RCP4.5 climate policy. RCP4.5 reduces GHG emissions by decreasing fossil 
fuel use substantially (replacing it with nuclear and renewable energy, primarily wind) and 
energy demand modestly, and by increasing forest cover and biofuels. Carbon capture and 
geologic storage grows such that it applies to nearly all electricity generation from fossil 
fuels and biofuels by 210018.
In REF, worldwide population-weighted metrics of ozone and PM2.5 in Fig. 1 decrease in 
2100 relative to 2000. Industrialized regions reduce emissions and improve air quality 
throughout the century, while many developing regions have worse air quality in 2030 
and/or 2050, before improving. Relative to REF, abating GHG emissions in RCP4.5 causes 
substantial reductions in ozone (8.1 ppb) and PM2.5 (2.4 μg m−3) in 2100. The 2100 ozone 
reduction is largely (89%) due to co-emitted air pollutants, with only 11% from the change 
in meteorology from climate change, and is strongly influenced by the large decrease in 
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methane emissions in RCP4.5. Changes in meteorology produce a small increase in global 
average PM2.5 relative to REF. In Fig. 2, meteorological changes in 2100 cause regional 
increases or decreases in PM2.5 that are small compared with the direct effect of co-emitted 
air pollutants. Slowing climate change decreases ozone in some polluted regions and over 
the Amazon where the increase in biogenic VOC emissions slows; it increases ozone in 
many remote areas, as it slows the increase of absolute humidity and HOx radicals that 
destroy ozone10.
In REF, global air pollution-related mortality increases in 2030 and then decreases, for both 
ozone and PM2.5 (Fig. 3). In North America, mortality decreases throughout the century, 
whereas mortality peaks in 2030 in East Asia and in 2050 in South Asia as air pollution 
controls are implemented more aggressively as these economies grow. In Africa, PM2.5 
mortality peaks in 2050, but ozone mortality grows to 2100. The global co-benefits of GHG 
mitigation, estimated as the difference between REF and RCP4.5, total 0.4±0.2, 1.1±0.5, and 
1.5±0.6 million avoided deaths yr−1 in 2030, 2050, and 2100 for PM2.5, and 0.09±0.06, 
0.2±0.1, and 0.7±0.5 million for ozone. In 2030, two-thirds of the global co-benefits occur 
in China (Fig. 4), as it has a large population and severe energy-related air pollution; the 
climate policy incentivizes changes away from conventional coal for electricity and 
industrial heat. In South Asia, there are little co-benefits in 2030 because of a shift toward 
biomass combustion in RCP4.5, and local PM2.5 increases in India due to climate change-
induced meteorological changes associated with the monsoon. But co-benefits are 
substantial in this region in 2050 and 2100 (0.5±0.2 and 1.1±0.4 million avoided deaths) as 
energy shifts away from fossil fuels and populations grow. In Africa, air pollution mortality 
increases in 2100 in REF, relative to 2000 concentrations, but deaths decrease in RCP4.5.
Co-benefits of avoided air pollution mortality are monetized using high and low values of a 
statistical life (VSLs), and are compared with the marginal costs of GHG reductions (the 
global carbon price) from 13 models meeting a 4.5 W m−2 target21. In 2030, the monetized 
mortality co-benefits exceed the median carbon price in all regions but Australia; in East 
Asia, co-benefits are 10–70 times the median cost (Fig. 5). In 2050, global average co-
benefits exceed the carbon price at both VSLs. By 2100, GHG reductions and costs increase 
markedly, as more expensive reduction measures are implemented, and co-benefits are 
within the low range of the carbon price. In 2050 and 2100, marginal co-benefits (assumed 
equal to the average co-benefit) are greatest in South Asia and East Asia. Marginal co-
benefits are largest in regions with high population affected by air pollution decreases, but 
also high in North America and Europe, reflecting high VSLs. Marginal co-benefits also do 
not vary strongly among time periods, but are highest in 2030 in more industrialized regions 
(including East Asia), because near-term reductions in air pollutant emissions leave less 
opportunity for co-benefits later. In less industrialized regions (e.g., South Asia, Africa), co-
benefits are highest in 2050 or 2100, reflecting rapid population and economic growth 
(increasing VSLs).
Monetized co-benefit estimates are $50–380 (ton CO2)−1 for the worldwide average, $30–
600 for the US and Western Europe, $70–840 for China, and −$20–400 for India (range 
includes differences over three years, high and low VSLs, and uncertainty in the 
concentration-response functions (CRFs)). These are higher than previous estimates of $1–
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128 for the US and Western Europe, and $6–196 for developing nations3–5, as we use new 
relationships for chronic mortality, account for ozone as well as PM2.5, model international 
air pollution transport and changes in global ozone from methane, and evaluate future 
scenarios in which population, susceptibility to air pollution, and VSLs grow. In a sensitivity 
analysis (Supplementary Information), we show that estimated future PM2.5 mortality co-
benefits may be substantially lower, under assumptions of a log-linear CRF or a high-
concentration threshold. We also show that future demographic changes (population growth, 
baseline mortality rates, and VSLs) have strong influences on the monetized co-benefits, 
particularly in 2100, and are likely an important factor in the higher co-benefits estimated 
here than in previous studies (Supplementary Information).
Monetized co-benefits could alternatively be evaluated as an avoided cost of air pollution 
controls, which would be lower than our estimates where the benefits of pollution controls 
exceed the costs. This approach could be estimated as the avoided air pollution controls 
needed to achieve air quality standards or air pollutant emission targets22,23. However, 
future air quality standards are unknown and this approach would neglect substantial health 
improvements from reductions below relevant standards. Future work should evaluate global 
co-benefits as avoided air pollution control costs, or as a combination of health benefits and 
avoided costs where both are evaluated relative to standards or emission targets. For 
example, global climate mitigation has been shown to avoid $100–600 billion yr−1 in air 
pollution control and energy security expenditures in 203024.
Co-benefits may be underestimated because we neglect people younger than 30, including 
effects on children and neonatal effects, and the benefits of avoided morbidity outcomes and 
ecosystem effects from reduced air pollution. Future work should quantify these additional 
air pollution co-benefits. In addition, the coarse spatial resolution of MOZART-4 likely 
underestimates PM2.5 exposure in cities, and the RCP emissions omit primary inorganic 
PM2.5 (fly ash), which is greatest in developing nations. We likewise neglect indoor air 
pollution, particularly from residential solid fuels25, which would be alleviated by some 
measures in RCP4.5. We caution that applying CRFs from the US globally and into the 
future entails large uncertainties. Co-benefits via the effects of climate change on air quality 
are small compared to the reduction of co-emitted air pollutants, but we neglect effects on 
fires and dust, which may be substantial26. Co-benefits are presented for the specific 
reference and GHG abatement scenarios modeled here, and would differ for other scenarios. 
In particular, if the air pollution controls built into REF were less aggressive, there would be 
greater potential for co-benefits. On the other hand, REF may not be consistent with recent 
decreases in SO2 emissions in China27, which could cause an overestimate of co-benefits. 
Co-benefits also depend on mitigation technology choices and national participation; where 
lower income countries delay entry into a climate policy, their co-benefits would likely 
decrease, while overall mitigation costs increase21.
In the global average and in many individual world regions, the co-benefits of avoided air 
pollution mortality can justify substantial reductions in GHG emissions, apart from other 
benefits of slowing global climate change. These results reflect the high premium that 
society places on avoiding death, through the VSLs used here. Decisions to mitigate GHG 
emissions should be motivated primarily by the benefits of slowing climate change, and air 
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pollutant emission reductions by the benefits of improving air quality. But decisions should 
also account for the full costs and benefits of proposed actions, as these results show the 
substantial air quality and health benefits of pursuing a low-carbon future. As these co-
benefits occur mainly locally, in the near term, and with high certainty, they contrast with 
the long-term distributed global benefits of slowing climate change, and therefore may be 
attractive to nations considering GHG reductions. Not all individual measures would bring 
such co-benefits. Therefore, there is a need to investigate the air quality co-benefits of 
specific alternatives in specific regions, while accounting for the international impacts of air 
pollution and long-term effects via methane and climate change. For policy, there is a need 
to better coordinate actions on air quality and climate change. By addressing both problems 
simultaneously, they may be managed more effectively, at less cost, and with greater overall 
benefits.
Methods
The MOZART-4 global chemical transport model28 is used to simulate ozone and PM2.5 air 
quality in 2000, 2030, 2050, and 2100. Anthropogenic emissions inputs of many species for 
REF were processed through the same steps as RCP4.5, which include speciating volatile 
organic compounds (VOCs) to MOZART-4 species by matching similar species, adding 
monthly emissions distributions to the annual total emissions, and regridding to a 2°×2.5° 
horizontal grid used for the MOZART-4 simulations. Biogenic VOC emissions are 
calculated online within MOZART-4, and therefore respond to changing climate conditions. 
Other natural emissions are from Emmons et al.28 and are assumed static, such that we 
neglect possible influences of climate change on emissions of dust, sea salt, and fires.
Meteorological inputs are from global general circulation model (GCM) simulations of 
RCP4.5 and RCP8.529 using the AM3 model. RCP8.5 climate is used as a proxy for REF 
climate since no climate simulations have been conducted for REF. The estimated global 
mean temperature change under REF is 3.6°C in 2095 (relative to the pre-industrial), while 
it is 4.5° for RCP8.5 and 2.3° for RCP4.5, using the MAGICC climate model. Co-benefits 
resulting from slowing future climate change are therefore biased high, but since these co-
benefits are shown to be small (Figs. 1 and 2), this bias is of little importance. By simulating 
REF emissions with meteorology from RCP4.5 (eREFm45), we separate the influences of 
changes in co-emitted air pollutants from those caused by climate change. For each 
scenario-year combination, five meteorological years are simulated with the first used as a 
spinup, and the average of four years is reported here to reduce the effects of meteorological 
variability.
Model performance relative to observations of ozone and PM2.5 species is comparable to 
other global models (Supplementary Information). Large contributions of dust made PM2.5 
estimates unrealistically large in arid regions, and so modeled dust concentrations were 
divided by 5 globally to roughly agree with the global surface concentrations of Brauer et 
al.30. We forced dust and sea salt concentrations to be the same in all simulations as we lack 
confidence in the modeled responses to changes in climate for these species; this choice 
does not influence our mortality estimates since mortality is based on the difference in 
PM2.5 between simulations. We also compared our simulated changes in regional and global 
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average ozone and PM2.5 concentrations in RCP4.5 in future years relative to 2000 against 
an ensemble of models, finding that our simulations are comparable (Supplementary 
Information). Concentrations in the lowest vertical coordinate are taken to represent ground-
level exposure.
Premature human mortality is estimated from modeled air pollutant concentrations using the 
methods of Anenberg et al.15 and CRFs based on the American Cancer Society study for 
chronic mortality from cardiopulmonary disease (CPD) and lung cancer for exposure to 
PM2.513, and chronic respiratory mortality for exposure to ozone14. Consistent with these 
studies, we evaluate premature mortality from chronic exposures for adults (30 years and 
older) using the annual average PM2.5 and the six-month ozone season average of 1-hour 
daily maximum ozone. These CRFs for cause-specific mortality are assumed to apply 
globally and into the future. Future population and baseline mortality rates are taken from 
International Futures (IFs)17, with global population growing to 9.7 billion in 2100. IFs 
accounts for changing causes of baseline mortality, capturing the future increase in the 
fraction of deaths by respiratory and CPD causes, and therefore increased susceptibility to 
air pollution. We use IFs to estimate the population and baseline rates of CPD, lung cancer, 
and respiratory mortality for the population above 30, in each country, which is then gridded 
to the 2°×2.5° grid using a geographic information system. For gridded population, we also 
use the spatial distribution of present-day population at fine resolution to distribute 
population within each country. Mortality calculations are conducted on the 2°×2.5° grid 
used by MOZART-4.
Avoided mortality is monetized using low and high VSLs (based on 2005 VSLs of $1.8 
million as a low value for Western Europe and $7.4 million for USA), which are adjusted to 
different world regions and into the future using an income elasticity of 0.5 (yielding 2030 
global means of $1.2 and $3.6 million) (Supplementary Information). All monetary values 
are expressed as 2005 US dollars. As most mortality benefits are from PM2.5 and influences 
of climate change on air quality are small, most avoided deaths result from co-emitted air 
pollutants in the same year; consequently, we simply compare marginal costs and benefits in 
the three modeled years, without discounting. The benefit curve with respect to CO2 
reductions is assumed to be flat, as there is little nonlinearity in the global air quality 
responses to changes in emissions and in the CRFs; marginal co-benefits are therefore 
estimated as the total co-benefits divided by the CO2 reduction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Global population-weighted surface (a) annual average PM2.5, and (b) 6-month ozone-
season average of 1-hr. daily maximum ozone, averaged over four model years, for the 
reference scenario (REF), the GHG abatement scenario (RCP4.5), and a simulation with 
REF emissions and RCP4.5 meteorology (eREFm45).
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Effects of GHG mitigation on annual average PM2.5 (μg m−3) and the 6-month ozone season 
average of daily 1-hr. maximum ozone (ppb) in 2100, averaged over four model years, for 
the total change (RCP4.5-REF), and components due to changes in meteorology from 
climate change (eREFm45-REF), and emissions (RCP4.5-eREFm45).
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Premature mortality from PM2.5 (CPD plus lung cancer) and ozone (respiratory), evaluated 
for future concentrations relative to 2000 levels, in the REF and RCP4.5 scenarios, globally 
and in selected world regions. Co-benefits can be estimated as the difference between REF 
and RCP4.5. In the global panel, points in 2100 are offset horizontally to show uncertainty 
bars, which reflect the 95% confidence intervals on the CRFs and neglect other 
uncertainties.
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Co-benefits of avoided premature mortality from PM2.5 (CPD plus lung cancer) and ozone 
(respiratory) in 2030, 2050, and 2100 (deaths per year per 1000 km2).
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Regional marginal co-benefits of avoided mortality under high (red) and low (blue) VSLs, 
and global marginal abatement costs (the carbon price), as the median (solid green line) and 
range (dashed green lines) of 13 models21. Marginal benefits are the total benefits (sum of 
ozone respiratory, PM2.5 CPD, and PM2.5 lung cancer mortality) divided by the total CO2 
reduction, in each year under RCP4.5 relative to REF. Uncertainty in benefits reflects 95% 
confidence intervals on the CRFs.
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